From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer

Matthew E. Spector, Andrew J. Rosko, Paul L. Swiecicki, J. Chad Brenner, Andrew C. Birkeland

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Organ preservation protocols utilizing induction chemotherapy as a selection agent have played a critical role in the treatment of advanced laryngeal squamous cell carcinoma (LSCC). The selection of patients who will have a good response to chemoradiation allows for organ preservation in a significant group of patients and minimizes the rate of surgical salvage. While there remains debate regarding its utility when compared to surgery or other organ preservation regimens, the data does suggest an important role for induction chemotherapy in LSCC. In addition, there are continued opportunities to identify pretreatment biomarkers for induction chemotherapy, whether genetic, epigenetic or cellular, that could predict response to treatment and select patients to therapy (whether organ preservation or surgery). As our understanding of the biology of larynx cancer advances, induction paradigms have utility for the development and adoption of novel agents and therapeutics. The background of induction chemotherapy as a selection agent and future directions of this approach are discussed.

Original languageEnglish (US)
Pages (from-to)200-205
Number of pages6
JournalOral Oncology
Volume86
DOIs
StatePublished - Nov 2018
Externally publishedYes

Fingerprint

Organ Preservation
Induction Chemotherapy
Laryngeal Neoplasms
Larynx
Squamous Cell Carcinoma
Therapeutics
Epigenomics
Patient Selection
Biomarkers

Keywords

  • Advanced laryngeal squamous cell carcinoma
  • Chemoselection
  • Induction selection
  • Organ preservation therapy

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

From VA Larynx to the future of chemoselection : Defining the role of induction chemotherapy in larynx cancer. / Spector, Matthew E.; Rosko, Andrew J.; Swiecicki, Paul L.; Chad Brenner, J.; Birkeland, Andrew C.

In: Oral Oncology, Vol. 86, 11.2018, p. 200-205.

Research output: Contribution to journalReview article

Spector, Matthew E. ; Rosko, Andrew J. ; Swiecicki, Paul L. ; Chad Brenner, J. ; Birkeland, Andrew C. / From VA Larynx to the future of chemoselection : Defining the role of induction chemotherapy in larynx cancer. In: Oral Oncology. 2018 ; Vol. 86. pp. 200-205.
@article{f9c55383d4584290a5a7dd382788cb8e,
title = "From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer",
abstract = "Organ preservation protocols utilizing induction chemotherapy as a selection agent have played a critical role in the treatment of advanced laryngeal squamous cell carcinoma (LSCC). The selection of patients who will have a good response to chemoradiation allows for organ preservation in a significant group of patients and minimizes the rate of surgical salvage. While there remains debate regarding its utility when compared to surgery or other organ preservation regimens, the data does suggest an important role for induction chemotherapy in LSCC. In addition, there are continued opportunities to identify pretreatment biomarkers for induction chemotherapy, whether genetic, epigenetic or cellular, that could predict response to treatment and select patients to therapy (whether organ preservation or surgery). As our understanding of the biology of larynx cancer advances, induction paradigms have utility for the development and adoption of novel agents and therapeutics. The background of induction chemotherapy as a selection agent and future directions of this approach are discussed.",
keywords = "Advanced laryngeal squamous cell carcinoma, Chemoselection, Induction selection, Organ preservation therapy",
author = "Spector, {Matthew E.} and Rosko, {Andrew J.} and Swiecicki, {Paul L.} and {Chad Brenner}, J. and Birkeland, {Andrew C.}",
year = "2018",
month = "11",
doi = "10.1016/j.oraloncology.2018.09.026",
language = "English (US)",
volume = "86",
pages = "200--205",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - From VA Larynx to the future of chemoselection

T2 - Defining the role of induction chemotherapy in larynx cancer

AU - Spector, Matthew E.

AU - Rosko, Andrew J.

AU - Swiecicki, Paul L.

AU - Chad Brenner, J.

AU - Birkeland, Andrew C.

PY - 2018/11

Y1 - 2018/11

N2 - Organ preservation protocols utilizing induction chemotherapy as a selection agent have played a critical role in the treatment of advanced laryngeal squamous cell carcinoma (LSCC). The selection of patients who will have a good response to chemoradiation allows for organ preservation in a significant group of patients and minimizes the rate of surgical salvage. While there remains debate regarding its utility when compared to surgery or other organ preservation regimens, the data does suggest an important role for induction chemotherapy in LSCC. In addition, there are continued opportunities to identify pretreatment biomarkers for induction chemotherapy, whether genetic, epigenetic or cellular, that could predict response to treatment and select patients to therapy (whether organ preservation or surgery). As our understanding of the biology of larynx cancer advances, induction paradigms have utility for the development and adoption of novel agents and therapeutics. The background of induction chemotherapy as a selection agent and future directions of this approach are discussed.

AB - Organ preservation protocols utilizing induction chemotherapy as a selection agent have played a critical role in the treatment of advanced laryngeal squamous cell carcinoma (LSCC). The selection of patients who will have a good response to chemoradiation allows for organ preservation in a significant group of patients and minimizes the rate of surgical salvage. While there remains debate regarding its utility when compared to surgery or other organ preservation regimens, the data does suggest an important role for induction chemotherapy in LSCC. In addition, there are continued opportunities to identify pretreatment biomarkers for induction chemotherapy, whether genetic, epigenetic or cellular, that could predict response to treatment and select patients to therapy (whether organ preservation or surgery). As our understanding of the biology of larynx cancer advances, induction paradigms have utility for the development and adoption of novel agents and therapeutics. The background of induction chemotherapy as a selection agent and future directions of this approach are discussed.

KW - Advanced laryngeal squamous cell carcinoma

KW - Chemoselection

KW - Induction selection

KW - Organ preservation therapy

UR - http://www.scopus.com/inward/record.url?scp=85054052246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054052246&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2018.09.026

DO - 10.1016/j.oraloncology.2018.09.026

M3 - Review article

C2 - 30409302

AN - SCOPUS:85054052246

VL - 86

SP - 200

EP - 205

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -